XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma
This study demonstrates XPO1 as a mediator TMZ resistance in MGMT-methylated GBM cells, and that MGMT expression status is a potential determinant of sensitivity to Selinexor/TMZ treatment in GBM cells. These findings also uncover a novel mechanism linking Selinexor with PKA-CREB-mediated MGMT expression, suggesting that Selinexor may enhance MGMT-dependent TMZ resistance in GBM.
Authors
- Jann Nagina Sarkaria (ORCID: https://orcid.org/0000-0001-7489-4885)
- Danielle M. Burgenske (ORCID: https://orcid.org/0000-0003-0014-5579)
- Yuta Suzuki (ORCID: https://orcid.org/0000-0002-8564-4491)
- Paul A. Decker (ORCID: https://orcid.org/0000-0002-3756-4227)
- Lin Zhang
- Jeanette E. Eckel-Passow (ORCID: https://orcid.org/0009-0001-5176-6378)
- Gaspar J. Kitange
- Josephine Mapunda
Institutions
- University of Minnesota (US)
- Mayo Clinic (US)
- Hormel (United States) (US)
- Mayo Clinic in Arizona (US)
- Minnesota Department of Health (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.3389/fonc.2025.1633580
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63